Dare Bioscience Inc. (NASDAQ:DARE) saw a downside of -1.85% to close Tuesday at $1.59 after subtracting -$0.03 on the day. The 5-day average trading volume is 1,123,420 shares of the company’s common stock. It has gained $1.6500 in the past week. An average of 1,916,185 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,349,374.
DARE’s 1-month performance is -5.36% or -$0.0600 on its low of $1.5400 reached on 10/11/21. The company’s shares have touched a 52-week low of $0.94 and high of $3.85, with the stock’s rally to the 52-week high happening on 01/20/21. YTD, DARE has achieved 18.66% or $0.2500. However, the current price is down -58.70%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Dare Bioscience Inc. (DARE) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.DARE stock has a beta of 1.62. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 10.60.
Dare Bioscience Inc.’s quick ratio for the period ended June 29 was 2.30, with the current ratio over the same period at 2.30 meaning that DARE stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00.
For the quarterly period ending June 29 this year, Analysts expected DARE to announce -$0.16 per share in earnings in its latest quarter, but it posted -$0.18, representing a -12.50% surprise. DARE stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 7.08 million, with total debt at $0.49 million. Shareholders hold equity totaling $70.52 million
Let’s look briefly at Dare Bioscience Inc. (DARE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 40.28% to suggest the stock is trending Neutral, with historical volatility in this time period at 27.67%.
The stock’s 5-day moving average is $1.5940, reflecting a +0.63% or $0.0100 change from its current price. DARE is currently trading -3.64% above its 20-day SMA, +20.45% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -0.62% and +12.77% respectively.
Stochastic %K and %D was 23.79% and 22.77% and the average true range (ATR) pointed at 0.0775. The RSI (14) points at 43.30%, while the 14-day stochastic is at 21.28% with the period’s ATR at 0.0809. The stock’s 9-day MACD Oscillator is pointing at -0.0111 and -0.0490 on the 14-day charts.
Analysts offering their rating for DARE stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate DARE as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is DARE’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.00 and a high of $11.00, with their median price target at $4.00. Looking at these predictions, the average price target given by analysts is for Dare Bioscience Inc. (DARE) stock is $5.50.